Diabetes-related outcomes with basal-bolus vs. premixed insulin among veterans with type 2 diabetes: A single institutional retrospective study

Background : Thepurposeofthisstudywastocomparediabetes(DM)-relatedoutcomesbetweenbasal-bolus(BB) andpremixed( PM) insulinregimens. Methods: Retrospectivechartreviewincludingveteranswithtype2diabetes(T2DM),>= 18yearsoldwithhemoglobinA1c( HbA1c)>= 8%. OutcomeswereassessedafteroneyearofBBorPMinsulintherapy. DatawereanalyzedusingChi-square/ Fisherexacttestsandlogisticregression. Results: Outof140enrolledsubjects(70BBand70PM), 94% weremaleswithaverageageanddurationofDMof65.7 +/- 10.1and12.9 +/- 9years, respectively. TheBBandPMgroupsweresimilarinage, genderdistribution, HbA1c, bodymassindex( BMI) andDMdurationatbaseline. Following1yearoftreatment, therewasnosignificantdifferencebetweenthegroupsforchangeinHbA1c(-1.9 +/- 1.8vs-2.1 +/- 1.9%, p= 0.3) orhypoglycemiarate(30% vs21.4%, p= 0.3), respectively. TherewassimilarincreaseinaverageBMIinbothgroups(0.84 +/- 3.1forBBvs0.4 +/- 2.2kg/m2forPM, p= 0.2). Conclusions: Therewerenosignificantdifferencesforglycemiccontrol, hypoglycemiarateorBMIbetweentheBBorPMinsulingroups. TheseresultssuggestPMinsulinisequallyeffectiveandsafeasBBinsulin.

Automated summary

This study aimed to compare diabetes-related outcomes between basal-bolus and premixed insulin regimens. The results showed no significant differences in glycemic control, hypoglycemia rate, or BMI between the two groups after one year of treatment. This suggests that premixed insulin is equally effective and safe as basal-bolus insulin.